Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase II Study of Siltuximab for CRS/ICANs After CAR-T in Multiple Myeloma
Sponsor: Institute of Hematology & Blood Diseases Hospital, China
Summary
This is a prospective Phase II study evaluating Siltuximab for CRS and ICANS after CAR-T infusion in multiple myeloma patients.
Official title: A Prospective, Single-Arm, Single-Center, Phase II Clinical Trial of Siltuximab for Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity After CAR-T Treatment in Multiple Myeloma
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2025-08-10
Completion Date
2027-08-01
Last Updated
2025-08-06
Healthy Volunteers
No
Conditions
Interventions
Siltuximab
Siltuximab 11mg/kg
Locations (1)
Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences
Tianjin, China